Sinopharm NVSI COVID-19 vaccine (NVSI-06-08) / Sinopharm - LARVOL DELTA

Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above (clinicaltrials.gov) - P1 | N=234 | Active, not recruiting | Sponsor: National Vaccine and Serum Institute, China | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Pneumonia

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. (PubMed, Nat Commun) - P1/2 | "Especially, the neutralizing antibody GMT against Omicron variant induced by heterologous NVSI-06-08 booster reaches 367.67, which is substantially greater than that boosted by BBIBP-CorV (GMT: 45.03). In summary, NVSI-06-08 is safe and immunogenic as a booster dose following two doses of BBIBP-CorV, which is immunogenically superior to the homologous boost with another dose of BBIBP-CorV."

Clinical • Journal • P2 data • P2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above (clinicaltrials.gov) - P1 | N=234 | Not yet recruiting | Sponsor: National Vaccine and Serum Institute, China

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia